The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO TAT 2022 | Unmet needs for early onset colorectal cancer
There has been a significant increase in early onset colorectal cancer (EO-CRC) over the last 10 years. Elisa Fontana, MD, PhD, Sarah Cannon Research Institute UK, London, UK, discusses recent research into the incidence of EO-CRC across Europe, and what research needs to be done to improve outcomes for these patients. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.
